Leaked Documents: Czech Republic Plans To Set Up Legal Recreational Cannabis Market

Written by Emily J. Thompson, Senior Investment Analyst

TLRY-0.88%

CGC+1.71%

WEED+3.74%

Source: Benzinga

Updated: Jul 15 2024

0mins

Source: Benzinga

Czech Republic Considering Legalizing Commercial Adult-Use Cannabis Market:
- The Czech Republic is contemplating a fully legal commercial adult-use cannabis market under the 'Cannabis Management Act,' with leaked documents indicating plans similar to Canada and certain US states.
- The proposed bill includes provisions for personal cultivation, licensing, and a regulated market, aiming to minimize illicit cannabis activities.
Major Cannabis Operators Expanding Presence in Czech Republic:
- Companies like Curaleaf International, PharmaCielo Ltd., Tilray Brands Inc., and Canopy Growth Corporation are expanding their operations in the Czech Republic in anticipation of potential regulatory changes towards a legal cannabis market.
- These expansions involve supply agreements, exports, and distribution partnerships to cater to the growing demand for medical cannabis products in the region.

TLRY

$9.05+Infinity%1D

Analyst Views on TLRY

Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Analyst Rating

1 Buy

3 Hold

0 Sell

Hold

Current: 9.130

Low

8.50

Averages

9.57

High

10.00

Current: 9.130

Low

8.50

Averages

9.57

High

10.00

Roth Capital

Neutral

downgrade

$20 -> $10

2026-01-20

New

Reason

Roth Capital

Price Target

$20 -> $10

AI Analysis

2026-01-20

New

downgrade

Neutral

Reason

Roth Capital lowered the firm's price target on Tilray to $10 from $20 and keeps a Neutral rating on the shares after its Q2 results. With a re-acceleration in international sales, strong Canadian adult-use performance , and an inflection at CC Pharma, Tilray looks poised to enter a period of stronger growth, though the upside for Tilray, unfortunately, will be predominantly determined by U.S. legislative outcomes, the analyst tells investors in a research note. Tilray had been on the leading edge of intoxicating hemp products, particularly among larger manufacturers, which faces potential ban on November 13, 2026, unless extended, the firm added.

Alliance Global

Aaron Grey

Neutral

downgrade

$20 -> $10

2026-01-09

Reason

Alliance Global

Aaron Grey

Price Target

$20 -> $10

2026-01-09

downgrade

Neutral

Reason

Alliance Global analyst Aaron Grey lowered the firm's price target on Tilray to $10 from $20 and keeps a Neutral rating on the shares. Tilray reported Q2 sales above the firm's and Street estimates, driven by higher distribution revenue and international sales, with EBITDA coming in slightly above the firm's Street-matching $7.9M estimate, the analyst tells investors. The firm views the quarter as in-line on a consolidated basis with some strengths offsetting some weaknesses, but remains on the sidelines as it looks for greater transparency to long-term sales and cash flow, the analyst added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TLRY

Unlock Now

Bernstein

Market Perform

maintain

$1 -> $10

2025-12-19

Reason

Bernstein

Price Target

$1 -> $10

2025-12-19

maintain

Market Perform

Reason

Bernstein raised the firm's price target on Tilray to $10 from $1 and keeps a Market Perform rating on the shares after President Trump signed an Executive Order related to cannabis. The firm says Tilray is positioned benefit from the regulatory changes. The company yesterday announced the formation of Tilray Medical USA, with the aim of drawing on its global experience in medical cannabis operations to win in the U.S., the analyst tells investors in a research note.

ATB Capital

Underperform -> Sector Perform

upgrade

$8.50

2025-12-10

Reason

ATB Capital

Price Target

$8.50

2025-12-10

upgrade

Underperform -> Sector Perform

Reason

ATB Capital upgraded Tilray to Sector Perform from Underperform with an $8.50 price target.

About TLRY

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.